The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management
Open accessAbstract
Herpes simplex viruses (HSV) type 1 and type 2 are responsible for recurrent orolabial and genital infections. The standard therapy for the management of HSV infections includes acyclovir (ACV) and penciclovir (PCV) with their respective prodrugs valacyclovir and famciclovir. These compounds are phosphorylated by the viral thymidine kinase (TK) and then by cellular kinases. The triphosphate forms selectively inhibit the viral DNA polymerase (DNA pol) activity. Drug-resistant HSV isolates are frequently recovered from immunocompromised patients but rarely found in immunocompetent subjects. The gold standard phenotypic method for evaluating the susceptibility of HSV isolates to antiviral drugs is the plaque reduction assay. Plaque autoradiography allows the associated phenotype to be distinguished (TK-wild-type, TK-negative, TK-low-producer, or TK-altered viruses or mixtures of wild-type and mutant viruses). Genotypic characterization of drug-resistant isolates can reveal mutations located in the viral TK and/or in the DNA pol genes. Recombinant HSV mutants can be generated to analyze the contribution of each specific mutation with regard to the drug resistance phenotype. Most ACV-resistant mutants exhibit some reduction in their capacity to establish latency and to reactivate, as well as in their degree of neurovirulence in animal models of HSV infection. For instance, TK-negative HSV mutants establish latency with a lower efficiency than wild-type strains and reactivate poorly. DNA pol HSV mutants exhibit different degrees of attenuation of neurovirulence. The management of ACV- or PCV-resistant HSV infections includes the use of the pyrophosphate analogue foscarnet and the nucleotide analogue cidofovir. There is a need to develop new antiherpetic compounds with different mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Fraunfelder, F. T. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90318-4 · Cited by 1,331
Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States
Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. M., & Markowitz, L. E. (2006) · JAMA · doi:10.1001/jama.296.8.964 · Cited by 1,035
Kennedy, C. O. (1971) · British Homeopathic Journal · doi:10.1016/s0007-0785(71)80027-3 · Cited by 974
Doorbar, J. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.006 · Cited by 856
Infections with Herpes Simplex Viruses
Corey, L., & Spear, P. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603133141105 · Cited by 778
Herpes simplex encephalitis: Adolescents and adults
Whitley, R. J. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.002 · Cited by 541
The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene
McKnight, S. L. (1980) · Nucleic Acids Research · doi:10.1093/nar/8.24.5949 · Cited by 528
Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., & Sutton, D. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.114-128.2003 · Cited by 504
Herpes simplex virus resistance to antiviral drugs
Morfin, F., & Thouvenot, D. (2003) · Journal of Clinical Virology · doi:10.1016/s1386-6532(02)00263-9 · Cited by 438
A conserved 3′→5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases
Bernad, A., Blanco, L., Lázaro, J., Martín, G., & Salas, M. (1989) · Cell · doi:10.1016/0092-8674(89)90883-0 · Cited by 435
Wong, S. W., Wahl, A. F., Yuan, P. M., Arai, N., Pearson, B. E., Arai, K., Korn, D., Hunkapiller, M. W., & Wang, T. S. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02781.x · Cited by 404
Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P., & Smiley, M. L. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.196 · Cited by 395
Wagstaff, A. J., Faulds, D., & Goa, K. L. (1994) · Drugs · doi:10.2165/00003495-199447010-00009 · Cited by 386
Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H. A., Landry, B., & Mills, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108223250805 · Cited by 375
Coen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, C. L., Schaffer, P. A., Tyler, K. L., & Knipe, D. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4736 · Cited by 362
Straus, S. E., Tariff, H. E., Seidlin, M., Bachrach, S., Lininger, L., DiGiovanna, J. J., Western, K. A., Smith, H. A., Lehrman, S. N., Creagh-Kirk, T., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406143102401 · Cited by 319
Tanaka, M., Kagawa, H., Yamanashi, Y., Sata, T., & Kawaguchi, Y. (2003) · Journal of Virology · doi:10.1128/jvi.77.2.1382-1391.2003 · Cited by 292
Treatment of Recurrent Genital Herpes Simplex Infections With Oral Acyclovir: A Controlled Trial
Reichman, R. C. (1984) · JAMA · doi:10.1001/jama.1984.03340400031020 · Cited by 290
Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase.
Miller, W. H., & Miller, R. L. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)79686-9 · Cited by 267
Related functional domains in virus DNA polymerases.
Larder, B. A., Kemp, S. D., & Darby, G. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb04735.x · Cited by 243
Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., & De Clercq, E. (1997) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632029700800101 · Cited by 243
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Perry, C. M., & Faulds, D. (1996) · Drugs · doi:10.2165/00003495-199652050-00009 · Cited by 240
Stránská, R., Schuurman, R., Nienhuis, E., Goedegebuure, I. W., Polman, M., Weel, J. F., Wertheim-Van Dillen, P. M., Berkhout, R. J. M., & van Loon, A. M. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.04.002 · Cited by 238
Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease
Crute, J. J., Grygon, C. A., Hargrave, K. D., Simoneau, B., Faucher, A.-M., Bolger, G., Kibler, P., Liuzzi, M., & Cordingley, M. G. (2002) · Nature Medicine · doi:10.1038/nm0402-386 · Cited by 232
Schnipper, L. E., & Crumpacker, C. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.2270 · Cited by 230
The Role of Herpes Simplex Virus Type 1 Thymidine Kinase in Pathogenesis
Efstathiou, S., Kemp, S., Darby, G., & Minson, A. C. (1989) · Journal of General Virology · doi:10.1099/0022-1317-70-4-869 · Cited by 230
Dix, R. D., McKendall, R. R., & Baringer, J. R. (1983) · Infection and Immunity · doi:10.1128/iai.40.1.103-112.1983 · Cited by 226
Replication of Herpes Simplex Virus DNA
Lehman, I. R., & Boehmer, P. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28059 · Cited by 215
Gottlieb, J., Marcy, A. I., Coen, D. M., & Challberg, M. D. (1990) · Journal of Virology · doi:10.1128/jvi.64.12.5976-5987.1990 · Cited by 213
Vere Hodge, R. A., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 210
Reitano, M., Tyring, S., Lang, W., Thoming, C., Worm, A. ‐., Borelli, S., Chambers, L. O., Robinson, J. M., Corey, L., & the International Valaciclovir HSV Study Group (1998) · The Journal of Infectious Diseases · doi:10.1086/515385 · Cited by 209
Herpes simplex virus type 1 DNA polymerase
Reardon, J. E., & Spector, T. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83248-3 · Cited by 207
A Cosmid-Based System for Constructing Mutants of Herpes Simplex Virus Type 1
Cunningham, C., & Davison, A. J. (1993) · Virology · doi:10.1006/viro.1993.1572 · Cited by 201
Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E. A., Tobler, K., Ackermann, M., Breakefield, X. O., & Fraefel, C. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2787 · Cited by 200
Spruance, S. L. (1997) · JAMA · doi:10.1001/jama.277.17.1374 · Cited by 189
An Enhanced Packaging System for Helper-Dependent Herpes Simplex Virus Vectors
Stavropoulos, T. A., & Strathdee, C. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7137-7143.1998 · Cited by 186
Gibbs, J. S., Chiou, H. C., Bastow, K. F., Cheng, Y. C., & Coen, D. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6672 · Cited by 182
Reyes, M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.76 · Cited by 181
Derse, D., Cheng, Y. C., Furman, P. A., St Clair, M. H., & Elion, G. B. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68420-6 · Cited by 180
Wade, J. C., McLaren, C., & Meyers, J. D. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/148.6.1077 · Cited by 180
Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase
Liu, S., Knafels, J. D., Chang, J. S., Waszak, G. A., Baldwin, E. T., Deibel, M. R., Thomsen, D. R., Homa, F. L., Wells, P. A., Tory, M. C., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602414200 · Cited by 178
Tyring, S. K., Baker, D., & Snowden, W. (2002) · The Journal of Infectious Diseases · doi:10.1086/342966 · Cited by 169
Neurological Complications of Herpes Simplex Virus Type 2 Infection
Berger, J. R., & Houff, S. (2008) · Archives of Neurology · doi:10.1001/archneur.65.5.596 · Cited by 167
Chen, Y., Scieux, C., Garrait, V., Socié, G., Rocha, V., Molina, J., Thouvenot, D., Morfin, F., Hocqueloux, L., Garderet, L., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/314052 · Cited by 165
Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient
Kost, R. G., Hill, E. L., Tigges, M., & Straus, S. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292405 · Cited by 162
Knopf, K.-W. (1979) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1979.tb13181.x · Cited by 157
Nugier, F., Colin, J., Aymard, M., & Langlois, M. (1992) · Journal of Medical Virology · doi:10.1002/jmv.1890360102 · Cited by 153
Spruance, S. L., Nett, R., Marbury, T. C., Wolff, R., Johnson, J. G., & Theodore Spaulding for The Acyclovir Cream Study Group (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2238-2243.2002 · Cited by 150
Diaz-Mitoma, F. (1998) · JAMA · doi:10.1001/jama.280.10.887 · Cited by 147 · cited 1×
“Clinical indications for oral ACV, VACV, and FCV include treatment of primary and recurrent HSV infections, particularly genital HSV (39, 168, 172, 206, 209), as well as chronic suppressive therapy to prevent genital herpes recurrences (72, 169, 216, 234).”
BackgroundGierasch, W. W., Zimmerman, D. L., Ward, S. L., Vanheyningen, T. K., Romine, J. D., & Leib, D. A. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.03.014 · Cited by 147
Ashkar, A. A., Yao, X.-D., Gill, N., Sajic, D., Patrick, A., & Rosenthal, K. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/425079 · Cited by 141
Phosphorylation of acyclovir diphosphate by cellular enzymes
Miller, W. H., & Miller, R. L. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90305-7 · Cited by 135
A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
Liuzzi, M., Déziel, R., Moss, N., Beaulieu, P. L., Bonneau, A.-M., Bousquet, C., Chafouleas, J. G., Garneau, M., Jaramillo, J., Krogsrud, R. L., et al. (1994) · Nature · doi:10.1038/372695a0 · Cited by 131
Chakrabarti, S., Pillay, D., Ratcliffe, D., Cane, P., Collingham, K. E., & Milligan, D. W. (2000) · The Journal of Infectious Diseases · doi:10.1086/315524 · Cited by 127
Hwang, C. B. C., Ruffner, K. L., & Coen, D. M. (1992) · Journal of Virology · doi:10.1128/jvi.66.3.1774-1776.1992 · Cited by 126
Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV‐Infected Patients
Levin, M. J., Bacon, T. H., & Leary, J. J. (2004) · Clinical Infectious Diseases · doi:10.1086/422364 · Cited by 126
Wild, K., Bohner, T., Folkers, G., & Schulz, G. E. (1997) · Protein Science · doi:10.1002/pro.5560061005 · Cited by 125
Erard, V., Wald, A., Corey, L., Leisenring, W. M., & Boeckh, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/518938 · Cited by 121
Infections in adults undergoing unrelated donor bone marrow transplantation
Williamson, E. C. M., Millar, M. R., Steward, C. G., Cornish, J., Foot, A. B. M., Oakhill, A., Pamphilon, D. H., Reeves, B. C., Caul, E. O., WARNOCK, D., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01229.x · Cited by 120
Mark, K. E., Corey, L., Meng, T., Magaret, A., Huang, M.-L. W., Selke, S., Slade, H. B., Tyring, S. K., Warren, T. J., Sacks, S. L., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/513276 · Cited by 112
Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
Clarke, S. E., Harrell, A. W., & Chenery, R. J. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06527-4 · Cited by 111
Herpes Simplex Virus Type 2 Meningoencephalitis Resistant to Acyclovir in a Patient with AIDS
Gateley, A., Gander, R. M., Johnson, P. C., Kit, S., Otsuka, H., & Kohl, S. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.4.711 · Cited by 111
Duan, R., de Vries, R. D., van Dun, J. M., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606028 · Cited by 107
Herpes simplex virus resistance to acyclovir: clinical relevance.
Pottage, J. C., & Kessler, H. A. (1995) · PubMed · Cited by 107
Kennedy, P. G. E. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0770-7 · Cited by 94
Balasubramaniam, N. K., Veerisetty, V., & Gentry, G. A. (1990) · Journal of General Virology · doi:10.1099/0022-1317-71-12-2979 · Cited by 93
Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability
Staskin, D. R., & MacDiarmid, S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.12.011 · Cited by 91
Frobert, É., Cortay, J., Ooka, T., Najioullah, F., Thouvenot, D., Lina, B., & Morfin, F. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.01.153 · Cited by 88
Langston, A. A., Redei, I., Caliendo, A. M., Somani, J., Hutcherson, D., Lonial, S., Bucur, S. Z., Cherry, J., Allen, A., & Waller, E. K. (2002) · Blood · doi:10.1182/blood.v99.3.1085 · Cited by 87
Wald, A., Selke, S., Warren, T. J., Aoki, F. Y., Sacks, S. L., Díaz‐Mitoma, F., & Corey, L. (2006) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000204723.15765.91 · Cited by 86
Digard, P., Bebrin, W. R., Weißhart, K., & Coen, D. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.1.398-406.1993 · Cited by 83
Hwang, Y. T., Liu, B., Coen, D. M., et al. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7791-7798.1997 · Cited by 81
Inhibition of human cytomegalovirus replication by small interfering RNAs
Wiebusch, L., Truß, M., & Hagemeier, C. (2004) · Journal of General Virology · doi:10.1099/vir.0.19453-0 · Cited by 79
Acyclovir resistance in herpes simplex encephalitis
Schulte, E. C., Sauerbrei, A., Hoffmann, D., Zimmer, C., Hemmer, B., & Mühlau, M. (2010) · Annals of Neurology · doi:10.1002/ana.21979 · Cited by 75
Herpes Simplex Virus Type 1 DNA Polymerase
Kühn, F. J. P., & Knopf, C. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.29245 · Cited by 69
Difference in Incidence of Spontaneous Mutations between Herpes Simplex Virus Types 1 and 2
Sarisky, R. T., Nguyen, T., Duffy, K. E., Wittrock, R. J., & Leary, J. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1524-1529.2000 · Cited by 68
Swetter, S. M., Hill, E. L., Kern, E. R., Koelle, D. M., Posavad, C. M., Lawrence, W., & Safrin, S. (1998) · The Journal of Infectious Diseases · doi:10.1086/514229 · Cited by 68
Boivin, N., Sergerie, Y., Rivest, S., & Boivin, G. (2008) · The Journal of Infectious Diseases · doi:10.1086/590671 · Cited by 65
Self-citationSchacker, T. W., Conant, M. A., Thoming, C., Stanczak, T. L., Wang, Z., & Smith, M. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3243-3248.2002 · Cited by 61
Kit, S., Sheppard, M., Ichimura, H., Nusinoff-Lehrman, S., Ellis, M., Fyfe, J. A., & Otsuka, H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.10.1483 · Cited by 61
Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia
Jacobson, J. G., Ruffner, K. L., Kosz‐Vnenchak, M., Hwang, C. B. C., Wobbe, K. K., Knipe, D. M., & Coen, D. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.11.6903-6908.1993 · Cited by 60
Boivin, G., Coulombe, Z., & Rivest, S. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02057.x · Cited by 55
Self-citationKellerman, S., McCombs, K., Ray, M., Baughman, W., Reeves, M. W., Popović, T., Rosenstein, N. E., Farley, M. M., Blake, P. A., Stephens, D. S., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/341067 · Cited by 54
Herpes simplex viruses 1 and 2
Yeung-Yue, K. A., Brentjens, M. H., Lee, P. C., & Tyring, S. K. (2002) · Dermatologic Clinics · doi:10.1016/s0733-8635(01)00003-1 · Cited by 54
Ziyaeyan, M., Alborzi, A., Japoni, A., Kadivar, M. R., Davarpanah, M. A., Pourabbas, B., & Abassian, A. (2007) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2007.03449.x · Cited by 53
Therapeutic potential of PMEA as an antiviral drug
Naesens, L. M. J., Balzarini, J. M., & Clercq, E. D. (1994) · Reviews in Medical Virology · doi:10.1002/rmv.1980040302 · Cited by 53
Baumeister, J., Fischer, R., Eckenberg, P., Henninger, K., Rübsamen‐Waigmann, H., & Kleymann, G. (2007) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020701800104 · Cited by 52
Bacon, T. H., Boon, R. J., Schultz, M., & Hodges-Savola, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3042-3044.2002 · Cited by 52
Fife, K. H., Meng, T., Ferris, D. G., & Liu, P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01173-07 · Cited by 50
Safrin, S., Cherrington, J. M., & Jaffe, H. S. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4743-3_10 · Cited by 49
Sarisky, R. T., Bacon, T. H., Boon, R. J., et al. (2003) · Archives of Virology · doi:10.1007/s00705-003-0124-7 · Cited by 46
Duan, J., Liuzzi, M., Paris, W., Lambert, M. V., Lawetz, C., Moss, N., Jaramillo, J., Gauthier, J. B., Déziel, R., & Cordingley, M. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1629 · Cited by 46
Cidofovir. Review of current and potential clinical uses.
Safrin, S., Cherrington, J. M., & Jaffe, H. (1999) · PubMed · Cited by 46
Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid
Datta, A. K., & Hood, R. E. (1981) · Virology · doi:10.1016/0042-6822(81)90251-8 · Cited by 44
Stránská, R., van Loon, A. M., Polman, M., & Schuurman, R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2943-2947.2002 · Cited by 44
Frequency of Acyclovir-Resistant Herpes Simplex Virus in Clinical Specimens and Laboratory Isolates
Shin, Y. K., Cai, G.-Y., Weinberg, A., Leary, J. J., & Levin, M. J. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.913-917.2001 · Cited by 44
Thi, T. H. V., Deback, C., Malet, I., et al. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.11.004 · Cited by 43
Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study
Bernstein, D. I., Spruance, S. L., Arora, S. S., Schroeder, J., & Meng, T. C. (2005) · Clinical Infectious Diseases · doi:10.1086/432802 · Cited by 43
Griffiths, A., Chen, S., Horsburgh, B. C., & Coen, D. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4703-4709.2003 · Cited by 42
Tanaka, M., Kodaira, H., Nishiyama, Y., Sata, T., & Kawaguchi, Y. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.01.011 · Cited by 41
Kopp, T., Geusau, A., Rieger, A., & Stingl, G. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04747.x · Cited by 40
Pavić, I., Hartmann, A., Zimmermann, A., Michel, D., Hampl, W., Schleyer, I., & Mertens, T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2686 · Cited by 40
Foster, S. A., Cerny, J., & Cheng, Y.-C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52426-1 · Cited by 37
Recurrent Herpes Simplex Virus Hepatitis After Liver Retransplantation Despite Acyclovir Therapy
Longerich, T., Eisenbach, C., Penzel, R., Kremer, T. L., Flechtenmacher, C., Helmke, B. M., Encke, J., Kraus, T. W., & Schirmacher, P. (2005) · Liver Transplantation · doi:10.1002/lt.20567 · Cited by 37
Verdonck, L., Cornelissen, J. J., Smit, J., et al. (1993) · PubMed · Cited by 36
Sacks, S. L., Aoki, F. Y., Martel, A. Y., Shafran, S. D., & Lassonde, M. (2005) · Clinical Infectious Diseases · doi:10.1086/444457 · Cited by 32
Ce, C., Sunstrum, J. C., Dr, A., et al. (1989) · PubMed · Cited by 32
Kaufman, H. E., Varnell, E. D., Gebhardt, B. M., Thompson, H. W., Atwal, E. S., Rübsamen‐Waigmann, H., & Kleymann, G. (2008) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2007.0084 · Cited by 26
Alvarez-Mcleod, A. P., Havlik, J. A., & Drew, K. E. (1999) · Clinical Infectious Diseases · doi:10.1086/520465 · Cited by 23
Bernstein, D. I., Ireland, J., & BOURNE, N. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00104-2 · Cited by 23
Weinberg, A., Leary, J. J., Sarisky, R. T., & Levin, M. J. (2006) · Journal of Clinical Virology · doi:10.1016/j.jcv.2006.08.023 · Cited by 21
Shin, Y. K., Weinberg, A., Spruance, S. L., Bernard, M., Bacon, T. H., Boon, R. J., & Levin, M. J. (2003) · The Journal of Infectious Diseases · doi:10.1086/373993 · Cited by 18
Testing the Susceptibility of Human Herpesviruses to Antivirals
Agut, H., Boutolleau, D., Deback, C., Bonnafous, P., & Gautheret-Dejean, A. (2009) · Future Microbiology · doi:10.2217/fmb.09.83 · Cited by 16
Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition): DNA Viruses
Field, H. J., & Clercq, E. D. (2008) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020801900203 · Cited by 16
Détection par génotypage de la résistance des virus herpes simplex à l'aciclovir
Frobert, É., Thouvenot, D., Lina, B., & Morfin, F. (2007) · Pathologie Biologie · doi:10.1016/j.patbio.2007.08.005 · Cited by 15
Clercq, E. D., & Field, H. J. (2008) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020801900204 · Cited by 15
Cited by
Targeting the “Cytokine Storm” for Therapeutic Benefit
D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00636-12 · Cited by 324
Torres, N. I., Noll, K. S., Xu, S., Li, J., Huang, Q., Sinko, P. J., Wachsman, M. B., & Chikindas, M. L. (2013) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-012-9123-x · Cited by 122
Hassan, S. T. S., Šudomová, M., Berchová-Bímová, K., Šmejkal, K., & Echeverría, J. (2019) · Molecules · doi:10.3390/molecules24162912 · Cited by 41
Metadata
- Authors
- Piret, J., & Boivin, G.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 459-472
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2043841254
- Cited by
- 558
- References
- 117
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.